Abstract
Alpha-synuclein is a presynaptic protein which is implicated in some neurodegenerative disorders including Parkinson’s disease, dementia with Lewy bodies, multiple systems atrophy, and Hallervorden-Spatz disease, and its overexpression contributes to the loss of dopaminergic neurons. Although the role of alpha-synuclein in these paradigms has been widely documented, its exact function is still elusive. And the dysfunction of the transcription factor nuclear factor (NF-κB) also exists in many neurodegenerative diseases. In this reason the purpose of this study was to investigate the molecular mechanism of alpha-synuclein’s toxicity and its association with NF-κB by MTT assay, Western blot method, and luciferase assay. Results showed that overexpressed alpha-synuclein and 1-methyl-4-phenylpyridinium (MPP+) suppressed the SH-SY5Y cell viability and attenuate NF-κB-mediated luciferase expression significantly. Moreover, the impairment function was enhanced with the increase of alpha-synuclein protein level. We also found that overexpressed alpha-synuclein localized both in the cytoplasms and nuclei, down-regulated the anti-apoptotic Bcl-2 expression and up-regulated the pro-apoptotic glycogen synthase kinase 3β (GSK3β) protein level. In conclusion, all these findings mentioned above suggested that alpha-synuclein shared some toxic functional homology with neurotoxin MPP+, and the proapoptotic effects of alpha-synuclein might be mediated at least in part by the impairment of NF-κB signaling pathway which involves GSK3β.




References
Aguilera C, Ferna’ndez-Majada V, Inglés-Esteve J, Rodilla V, Espinosa L (2006) Efficient nuclear export of p65-IkBa complexes requires 14-3-3 proteins. J Cell Sci 119:3695–3704
Arawaka S, Saito Y, Murayama S, Mori H (1998) Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology 51:887–889
Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol 152:879–884
Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR (1997) Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 275:1930–1933
Bernheimer H, Birkmayer W, Hornykiewicz O, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415–455
Bhakar AL, Tannis LL, Zeindler C, Russo MP, Jobin C, Park DS (2002) Constitutive nuclear factor-kappa B activity is required for central neuron survival. J Neurosci 22:8466–8475
Boyle WJ, Smeal T, Defize LH, Angel P, Woodgett JR, Karin M, Hunter T (1991) Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 64:573–584
Catz SD, Johnson JL (2001) Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20:7342–7351
Claton DJ, George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58:120–129
Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD (2001) Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death. J Neurochem 77:94–102
Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302:819–822
Dickson DW, Liu W-K, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D’Amato C, Albin R, Gilman S, Yen S-H (1999) Widespread alterations of α-synuclein in multiple system atrophy. Am J Pathol 155:1241–1251
Dunnett SB, Bjorklund A (1999) Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature 399:A32–A39
Fall CP, Bennett Jr JP (1999) Characterization and time course of MPP+-induced apoptosis in human SH-SY5Y neuroblastoma cells. J Neurosci Res 55:620–628
Ginger RS, Dalton EC, Ryves WJ, Fukuzawa M, Williams JG, Harwood AJ (2000) Glycogen synthase kinase-3 enhances nuclear export of a Dictyostelium STAT protein. EMBO J 19:5483–5491
Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, Di Monte DA, Uversky VN, Fink AL (2003) Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 42:8465–8471
Gómez-Santos, Ferrer I, Reiriz J, Vinals F, Barrachina M, Ambrosio S (2002) MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 935:32–39
Grimes CA, Jope RS (2001a) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem 78:1219–1232
Grimes CA, Jope RS (2001b) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65:391–426
Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes & Dev 13:1899–1904
Halvorsen EM, Dennis J, Keeney P, Sturgill TW, Tuttle JB, Bennett Jr JB (2002) Methylpyridinium (MPP(+))- and nerve growth factor-induced changes in pro- and anti-apoptotic signaling pathways in SH-SY5Y neuroblastoma cells. Brain Res 952:98–110
Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469
Hetman M, Cavanaugh JE, Kimelman D, Xia Z (2000) Role of glycogen synthase kinase-3 in neuronal apoptosis induced by trophic withdrawal. J Neurosci 20:2567–2574
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, Silva HA, Kittel A, Saitoh T (1995) The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467–475
Iwata A, Miura S, Kanazawa I, Sawada M, Nukina N (2001) alpha-Synuclein forms a complex with transcription factor Elk-1. J Neurochem 77:239–252
Kontopoulos E, Parvin JD, Feany MB (2006) α-Synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 15:3012–3023
Langston JW (1996) The etiology of Parkinson’s disease with emphasis on the MPTP story. Neurology 47:153–160
Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Price DL (2002) Human α-synuclein-harboring familial Parkinson’s disease-linked Ala-53 Thr mutation causes neurodegenerative disease with -synuclein aggregation in transgenic mice. PNAS 99:8968–8973
Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8:2804–2815
Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287:1265–1267
Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D (2003) NF-kappa B functions in synaptic signaling and behavior. Nat Neurosci 6:1072–1078
Meller N, Liu YC, Collins TL, Bonnefoy-Berard N, Baier G, Isakov N, Altman A (1996) Direct interaction between protein kinase C theta (PKC theta) and 14-3- 3 tau in T cells: 14-3-3 overexpression results in inhibition of PKC theta translocation and function. Mol Cell Biol 16:5782–5791
Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B (1999) α-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19:5782–5791
Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. Neurosci 22:3090–3099
Planel E, Sun X, Takashima A (2002) Role of GSK-3β in Alzheimer’s disease pathology. Drug Dev 56:491–510
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Iorio GD, Golbe LI, Nussbaum RL (1997) Mutation in the α-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047
Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S, Maggirwar SB (2003) Glycogen synthase kinase 3β mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kB signaling. Mol Cell Biol 23:4639–4662
Specht CG, Tigaret CM, Rast GF, Thalhammer A, Rudhard Y, Schoepfer R (2005) Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol Cell Neurosci 28:326–334
Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. PNAS 95:6469–6473
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840
Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P (1999) A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett 458:247–251
Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi T (1998) Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249:180–182
Wang C-Y, Guttridge DC, Mayo MW, Baldwin AS (1999) NF-kB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19:5923–5929
Xu J, Kao SY, Lee FJ, Song W, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600–606
Xu J, Zhong N, Wang H, Elias JE, Kim CY, Woldman I, Pifl C, Gygi SP, Geula C, Yankner BA (2005) The Parkinson’s disease-associated DJ-1 protein is a transcriptional co-activator that protects against neuronal apoptosis. Hum Mol Genet 14:1231–1241
Yu S, Zuo X, Li Y, Zhang C, Zhou M, Zhang YA, Ueda K, Chan P (2004) Inhibition of tyrosine hydroxylase expression in alpha-synuclein-transfected dopaminergic neuronal cells. Neurosci Lett 367:34–39
Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ (1996) Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 86:619–628
Zhang L, Wang H, Liu D, Liddington R, Fu H (1997) Raf-1 kinase and exoenzyme s interact with 14-3-3 g through a common site involving lysine 49. J Biol Chem 272:13717–13724
Zigmond MJ, Stricker EM (1989) Animal models of parkinsonism using selective neurotoxins: clinical and basic implications. Int Rev Neurobiol 31:1–79
Acknowledgments
This work was supported by National Key Basic Research & Development Program (973 project Grant No. 2004CB518906), Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT No. IRT0514) and the National Natural Science Foundation of China (No. 30572342 and No. 30271499).
Author information
Authors and Affiliations
Corresponding author
Additional information
Yuhe Yuan and Jin Jin contributed equally to this article.
Rights and permissions
About this article
Cite this article
Yuan, Y., Jin, J., Yang, B. et al. Overexpressed Alpha-Synuclein Regulated the Nuclear Factor-kappaB Signal Pathway. Cell Mol Neurobiol 28, 21–33 (2008). https://doi.org/10.1007/s10571-007-9185-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-007-9185-6